Evidence map›Paper›PMID 38230295›Full record

ArticleACS pharmacology & translational science2024

In-Depth Structure and Function Characterization of Heterogeneous Interchain Cysteine-Conjugated Antibody-Drug Conjugates.

Huijie Chen, Danye Qiu, Jian Shi, Ningning Wang, Muchen Li, Ying Wu, Yu Tian, Xiaodong Bu, Qingyuan Liu, Yanrui Jiang and 3 more

Abstract read
In one paragraph

Article in ACS pharmacology & translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Huijie ChenAnalytical Sciences, WuXi Biologics, 31 Yiwei Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.ORCID https://orcid.org/0009-0002-9157-9320
Danye QiuAnalytical Sciences, WuXi Biologics, 1150 Lanfeng Road, Fengxian District, Shanghai 201403, China.
Jian ShiAnalytical Sciences, WuXi Biologics, 31 Yiwei Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
Ningning WangWuXi Process Development Analytical Science, WuXi Biologics, 200 Meiliang Road, Binhu District, WuXi, Jiangsu 214092, China.
Muchen LiWuXi Process Development Analytical Science, WuXi Biologics, 200 Meiliang Road, Binhu District, WuXi, Jiangsu 214092, China.
Ying WuAnalytical Sciences, WuXi Biologics, 31 Yiwei Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
Yu TianBiologics Innovation & Discovery, WuXi Biologics, 227 Meisheng Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China.
Xiaodong BuAnalytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0001-6868-0282
Qingyuan LiuAnalytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Yanrui JiangAnalytical Research & Development, MSD, Industrie Nord 1, Schachen (Luzern) CH-6105, Switzerland.
Simon E HamiltonAnalytical Research & Development, MSD, 120 Moorgate, London EC2M 6UR, U.K.
Ping HanAnalytical Research & Development, Merck & Co., Inc., 2000 Galloping Hill Road, Kenilworth, New Jersey 07033, United States.
Shuwen SunAnalytical Research & Development, Merck & Co., Inc., 126 E. Lincoln Avenue, Rahway, New Jersey 07065, United States.ORCID https://orcid.org/0000-0002-9612-1135

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibody-drug conjugates (ADCs), integrating high specificity of antigen-targeting antibodies and high potency of cell-killing chemical drugs, have become one of the most rapidly expanding therapeutic biologics in oncology. Although ADCs were widely studied from multiple aspects, overall structural elucidation with comprehensive understanding of variants is scarcely reported. Here, for the first time, we present a holistic and in-depth characterization of an interchain cysteine-conjugated ADC, focusing on conjugation and charge heterogeneity, and in vitro biological activities. Conjugation mapping utilized a bottom-up approach, unraveled positional isomer composition, provided insights into the conjugation process, and elucidated how conjugation affects the physicochemical and biological properties of an ADC. Charge profiling combined bottom-up and top-down approaches to interrogate the origin of charge heterogeneity, its impact on function, and best practice for characterization. Specifically, we pioneered the utilization of capillary isoelectric focusing-mass spectrometry to decode not only critical post-translational modifications but also drug load and positional isomer distribution. The study design provides general guidance for in-depth characterization of ADCs, and the analytical findings in turn benefit the discovery and development of future ADCs.

Identifiers

PMID38230295
PMCPMC10789146

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.